

User Experience Survey Results¹

Satisfaction Rates

Soar For SENVELGO®



GB packaging shown for illustrative purpose

Background

Diabetes mellitus (DM) is a common feline endocrinopathy, historically resulting in euthanasia in ~20% of affected cats within the first 12 months due to insulin related challenges.² In 2023, SENVELGO® Oral Solution for Cats (velagliflozin), a sodium-glucose co-transporter-2 inhibitor, was approved in the UK, USA and Europe, allowing the treatment of feline diabetes without the need for insulin injections. This innovative solution only has to be administered once daily, either directly in the cat's mouth or applied to a small amount of food.

This survey aimed to investigate veterinary professional and owner experiences using SENVELGO®. Participants were asked to complete a questionnaire relating to their experiences. Responses were collected from November 2024 to February 2025. In total, 325 completed questionnaires were received from 175 veterinary professionals from Germany, the Netherlands and the UK, and from 150 pet owners from the USA.


Results

SENVELGO® is delivering positive experiences for veterinary professionals and cat owners around the world.

96% of veterinary professionals either agreed or strongly agreed that SENVELGO® improved cats' and owners' quality of life.


How much do you (veterinary professionals) agree or disagree with the following statement?

SENVELGO® improves cats' and owners' quality of life & allows them to live normal lives despite this disease.



How satisfied is the owner with treating their diabetic cat with SENVELGO®?

Combined results from veterinary surgeons and owners show strong satisfaction rates among cat owners.




93.1% of veterinary surgeons and 86.7% of owners reported that owners were satisfied or very satisfied with SENVELGO®.

More reasons to consider SENVELGO®


Vets and owners felt that SENVELGO® was easy to give.

Agreed or strongly agreed that SENVELGO® was easy to give:



How likely are you (vet) to recommend SENVELGO® to another veterinary surgeon?

Vets who have used SENVELGO® highly recommend it for feline diabetes.



Paradigm Shift

94.3%

of vet professionals either agreed or strongly agreed that SENVELGO® has provided a **paradigm shift in the treatment of feline diabetes.**

Liquid Preference

97.1%

Vet professionals reported that 97.1% of owners either agreed or strongly agreed that **owners preferred to treat their cat with a once-daily liquid versus twice-daily injections.**

Conclusion:

These results show that vets and owners who have used SENVELGO® believe it provides a paradigm-shift in the management of feline diabetes, improving the quality of life for diabetic cats and their owners with an easy to give, once daily oral solution.

¹Besson A, Watson A. H., Zimmering T. M., Orlov P, Improved Quality of Life in diabetic cats receiving SENVELGO® - First results of a global User Experience Survey. Poster presented at World Feline Congress 2025; 27-29 June 2025, Edinburgh, UK.

²Niessen, S. J. M. et al. (2017) The Big Pet Diabetes Survey: Perceived Frequency and Triggers for Euthanasia. Vet Sci 4, 27.

Senvelgo® contains velagliflozin (sodium-glucose co-transporter 2 [SGLT-2] inhibitor). UK: POM-V IE: POM. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email: veterenquiries@boehringer-ingelheim.com. Senvelgo® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2025 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Aug 2025. UI-PET-0255-2025. Use Medicines Responsibly. Prescription decisions are for the person issuing the prescription alone.